rotenone has been researched along with Cortical Lewy Body Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Imai, Y | 1 |
| Davis, A; Meedeniya, ACB; Pountney, DL; Rcom-H'cheo-Gauthier, AN | 1 |
2 other study(ies) available for rotenone and Cortical Lewy Body Disease
| Article | Year |
|---|---|
Editorial for the Special Issue "Animal Models of Parkinson's Disease and Related Disorders".
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Early Diagnosis; Humans; Lewy Body Disease; Oxidopamine; Parkinson Disease; Rotenone | 2020 |
Alpha-synuclein aggregates are excluded from calbindin-D28k-positive neurons in dementia with Lewy bodies and a unilateral rotenone mouse model.
Topics: Aged; Aged, 80 and over; alpha-Synuclein; Animals; Calbindin 1; Humans; Lewy Body Disease; Mice; Mice, Inbred C57BL; Neurons; Oxidative Stress; Protein Aggregates; Rotenone | 2016 |